165 related articles for article (PubMed ID: 29858958)
1. Process optimization for the rapid production of adenoviral vectors for clinical trials in a disposable bioreactor system.
Chen KD; Wu XX; Yu DS; Ou HL; Li YH; Zhou YQ; Li LJ
Appl Microbiol Biotechnol; 2018 Aug; 102(15):6469-6477. PubMed ID: 29858958
[TBL] [Abstract][Full Text] [Related]
2. [Producing Ad-IFN gamma by suspension culture of HEK293 cells in a disposable bioreactor].
Wu Q; Huang W
Sheng Wu Gong Cheng Xue Bao; 2014 Nov; 30(11):1786-90. PubMed ID: 25985530
[TBL] [Abstract][Full Text] [Related]
3. Process Development of Adenoviral Vector Production in Fixed Bed Bioreactor: From Bench to Commercial Scale.
Lesch HP; Heikkilä KM; Lipponen EM; Valonen P; Müller A; Räsänen E; Tuunanen T; Hassinen MM; Parker N; Karhinen M; Shaw R; Ylä-Herttuala S
Hum Gene Ther; 2015 Aug; 26(8):560-71. PubMed ID: 26176404
[TBL] [Abstract][Full Text] [Related]
4. Production of oncolytic adenovirus and human mesenchymal stem cells in a single-use, Vertical-Wheel bioreactor system: Impact of bioreactor design on performance of microcarrier-based cell culture processes.
Sousa MF; Silva MM; Giroux D; Hashimura Y; Wesselschmidt R; Lee B; Roldão A; Carrondo MJ; Alves PM; Serra M
Biotechnol Prog; 2015; 31(6):1600-12. PubMed ID: 26289142
[TBL] [Abstract][Full Text] [Related]
5. Benchmarking of Scale-X Bioreactor System in Lentiviral and Adenoviral Vector Production.
Leinonen HM; Lepola S; Lipponen EM; Heikura T; Koponen T; Parker N; Ylä-Herttuala S; Lesch HP
Hum Gene Ther; 2020 Mar; 31(5-6):376-384. PubMed ID: 32075423
[TBL] [Abstract][Full Text] [Related]
6. Integrated strategy for the production of therapeutic retroviral vectors.
Carrondo M; Panet A; Wirth D; Coroadinha AS; Cruz P; Falk H; Schucht R; Dupont F; Geny-Fiamma C; Merten OW; Hauser H
Hum Gene Ther; 2011 Mar; 22(3):370-9. PubMed ID: 21043806
[TBL] [Abstract][Full Text] [Related]
7. Optimization and scale-up of cell culture and purification processes for production of an adenovirus-vectored tuberculosis vaccine candidate.
Shen CF; Jacob D; Zhu T; Bernier A; Shao Z; Yu X; Patel M; Lanthier S; Kamen A
Vaccine; 2016 Jun; 34(29):3381-7. PubMed ID: 27154390
[TBL] [Abstract][Full Text] [Related]
8. Large-scale clinical-grade retroviral vector production in a fixed-bed bioreactor.
Wang X; Olszewska M; Qu J; Wasielewska T; Bartido S; Hermetet G; Sadelain M; Rivière I
J Immunother; 2015 Apr; 38(3):127-35. PubMed ID: 25751502
[TBL] [Abstract][Full Text] [Related]
9. Production of Recombinant Adeno-associated Virus Vectors Using Suspension HEK293 Cells and Continuous Harvest of Vector From the Culture Media for GMP FIX and FLT1 Clinical Vector.
Grieger JC; Soltys SM; Samulski RJ
Mol Ther; 2016 Feb; 24(2):287-297. PubMed ID: 26437810
[TBL] [Abstract][Full Text] [Related]
10. Development and Optimization of AAV hFIX Particles by Transient Transfection in an iCELLis(®) Fixed-Bed Bioreactor.
Powers AD; Piras BA; Clark RK; Lockey TD; Meagher MM
Hum Gene Ther Methods; 2016 Jun; 27(3):112-21. PubMed ID: 27229773
[TBL] [Abstract][Full Text] [Related]
11. An efficient and scalable process for helper-dependent adenoviral vector production using polyethylenimine-adenofection.
Dormond E; Meneses-Acosta A; Jacob D; Durocher Y; Gilbert R; Perrier M; Kamen A
Biotechnol Bioeng; 2009 Feb; 102(3):800-10. PubMed ID: 18821637
[TBL] [Abstract][Full Text] [Related]
12. Development and optimization of an adenovirus production process.
Kamen A; Henry O
J Gene Med; 2004 Feb; 6 Suppl 1():S184-92. PubMed ID: 14978761
[TBL] [Abstract][Full Text] [Related]
13. Optimization of HEK-293S cell cultures for the production of adenoviral vectors in bioreactors using on-line OUR measurements.
Gálvez J; Lecina M; Solà C; Cairó JJ; Gòdia F
J Biotechnol; 2012 Jan; 157(1):214-22. PubMed ID: 22119332
[TBL] [Abstract][Full Text] [Related]
14. Serum-free production of recombinant proteins and adenoviral vectors by 293SF-3F6 cells.
Côté J; Garnier A; Massie B; Kamen A
Biotechnol Bioeng; 1998 Sep; 59(5):567-75. PubMed ID: 10099373
[TBL] [Abstract][Full Text] [Related]
15. Optimization of Vero Cells Grown on a Polymer Fiber Carrier in a Disposable Bioreactor for Inactivated Coxsackievirus A16 Vaccine Development.
Chen K; Li C; Wang Y; Shen Z; Guo Y; Li X; Zhang Y
Vaccines (Basel); 2021 Jun; 9(6):. PubMed ID: 34200441
[TBL] [Abstract][Full Text] [Related]
16. Manufacturing of adenovirus vectors: production and purification of helper dependent adenovirus.
Dormond E; Kamen AA
Methods Mol Biol; 2011; 737():139-56. PubMed ID: 21590396
[TBL] [Abstract][Full Text] [Related]
17. Production of influenza H1N1 vaccine from MDCK cells using a novel disposable packed-bed bioreactor.
Sun B; Yu X; Kong W; Sun S; Yang P; Zhu C; Zhang H; Wu Y; Chen Y; Shi Y; Zhang X; Jiang C
Appl Microbiol Biotechnol; 2013 Feb; 97(3):1063-70. PubMed ID: 22945265
[TBL] [Abstract][Full Text] [Related]
18. State-of-the-art of the production of retroviral vectors.
Merten OW
J Gene Med; 2004 Feb; 6 Suppl 1():S105-24. PubMed ID: 14978755
[TBL] [Abstract][Full Text] [Related]
19. Production of viral vectors for gene therapy applications.
Wu N; Ataai MM
Curr Opin Biotechnol; 2000 Apr; 11(2):205-8. PubMed ID: 10753765
[TBL] [Abstract][Full Text] [Related]
20. GMP-Compliant Adenoviral Vectors for Gene Therapy.
Arjmand B; Alavi-Moghadam S; Payab M; Goodarzi P; Sheikh Hosseini M; Tayanloo-Beik A; Rezaei-Tavirani M; Larijani B
Methods Mol Biol; 2021; 2286():237-250. PubMed ID: 32504293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
